The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Greten, Stephan; Wegner, Florian; Jensen, Ida; Krey, Lea; Rogozinski, Sophia; Fehring, Meret; Heine, Johanne; Doll-Lee, Johanna; Pötter-Nerger, Monika; Zeitzschel, Molly; Hagena, Keno; Pedrosa, David J; Eggers, Carsten; Bürk, Katrin; Trenkwalder, Claudia; Claus, Inga; Warnecke, Tobias; Süß, Patrick; Winkler, Jürgen; Gruber, Doreen; Gandor, Florin; Berg, Daniela Dagmar Denise; Paschen, Steffen; Classen, Joseph; Pinkhardt, Elmar H; Kassubek, Jan; Jost, Wolfgang H; Tönges, Lars; Kühn, Andrea A; Schwarz, Johannes; Peters, Oliver; Dashti, Eman; Priller, Josef; Spruth, Eike J; Krause, Patricia; Spottke, Annika; Schneider, Anja; Beyle, Aline; Kimmich, Okka; Donix, Markus; Haussmann, Robert; Brandt, Moritz; Dinter, Elisabeth; Wiltfang, Jens; Schott, Björn H; Zerr, Inga; Bähr, Mathias; Buerger, Katharina; Janowitz, Daniel; Perneczky, Robert; Rauchmann, Boris-Stephan; Weidinger, Endy; Levin, Johannes; Katzdobler, Sabrina; Düzel, Emrah; Glanz, Wenzel; Teipel, Stefan; Kilimann, Ingo; Prudlo, Johannes; Gasser, Thomas; Brockmann, Kathrin; Hoffmann, Daniel; Klockgether, Thomas; Krause, Olaf; Heck, Johannes; Höglinger, Günter U; Klietz, Martin

Background

Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.

Objectives

To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.

Methods

Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik®.

Results

In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.

Conclusions

PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

Rechte

Nutzung und Vervielfältigung:


CC BY 4.0

Bitte beachten Sie, dass einzelne Bestandteile der Publikation anderweitigen Lizenz- bzw. urheberrechtlichen Bedingungen unterliegen können.

Zitieren

Zitierform:
Zitierform konnte nicht geladen werden.